Jan Garfinkle
QuietNamed in filings at Arboretum VenturesOn the current fund
- Board seats filed
- 9
- Named on a board
- 0
all filings on record
Named in filings at Arboretum VenturesOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Reprieve Cardiovascular | Not yet classified | November 2023 | None on file |
| RareCyte | Not yet classified | August 2021 | None on file |
| Koya Medical | Not yet classified | December 2020 | None on file |
| Francis Medical | Not yet classified | November 2018 | None on file |
| Strata Oncology | Biotech & pharma | April 2018 | Baird Venture Partners, BVP |
| Arbor Bancorp | Not yet classified | December 2016 | None on file |
| NXTHERA | Not yet classified | February 2015 | None on file |
| SONITUS MEDICAL | Medical devices | April 2014 | Abingworth Bioventures |
| NeuMoDx Molecular | Medical devices | March 2014 | Baird Venture Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Jan Garfinkle on the board, based on 3 filed seats with a verified or cited source.
6 more filed seats not yet classified, left out of the shares above.